Spencer Feldman

Innovent dosed the first patient in a phase 3 trial of IBI354, an anti-HER2 antibody-drug conjugate for platinum-resistant ovarian cancer. The first patient has been successfully dosed with IBI354 in the phase 3 clinical trial HeriCare-Ovarian01 for patients with platinum-resistant […]

Dr. Zachariah H. Froda discusses colorectal cancer warning signs like rectal bleeding, unexplained weight loss, and bowel habit changes, emphasizing awareness, early detection and prevention. In honor of Colorectal Cancer Awareness Month, Dr. Zachariah H. Foda, who is the Assistant

Pathos AI initiates a phase 1b/2a trial evaluating pocenbrodib for metastatic prostate cancer, testing it alone or with Zytiga, Lynparza or Pluvicto. The first patent has been dosed in the phase 1b/2a clinical trial P300-02-001, which is evaluating pocenbrodib alone,

FDA grants fast track designation to azer-cel in relapsed/refractory DLBCL: © stock.adobe.com The U.S. Food and Drug Administration (FDA) has granted fast track designation to the allogenic CAR T-cell therapy azer-cel (azercabtagene zapreleucel) for the treatment of patients with relapsed

Gavreto is a preferred first-line treatment for metastatic RET fusion-positive NSCLC, with FDA approval based on the ARROW study and potential severe side effects. For patients diagnosed with RET fusion-positive, metastatic non-small cell lung cancer (NSCLC), understanding treatment options is

Elevation Oncology discontinues EO-3021 for gastric and GEJ cancers after phase 1 trial shows insufficient efficacy, focusing on advancing EO-1022 instead. Elevation Oncology announced that it has elected to discontinue development of EO-3021, an antibody-drug conjugate (ADC), which was being

Gene expression testing helps determine the necessity of chemotherapy in hormone receptor-positive breast cancer, optimizing treatment and minimizing unnecessary toxicity. Breast cancer treatment continues to evolve with advancements in gene expression testing and targeted therapies, helping to refine treatment decisions

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression. The U.S. Food and Drug Administration (FDA) has granted traditional approval to treatment with Keytruda (pembrolizumab) plus Herceptin (trastuzumab) and fluoropyrimidine- and platinum-containing chemotherapy

Genetic and genomic testing are key in breast cancer risk and treatment, with Dr. Mark Robson explaining their evolving roles at the Miami Breast Cancer Summit. Genetic and genomic testing play a critical role in understanding breast cancer risk and

Orca-T improved survival free of moderate-to-severe cGVHD across leukemia subtypes: © nobeastsofierce – stock.adobe.com. Orca-T, a T-cell immunotherapy, significantly improved survival free of moderate-to-severe chronic graft-versus-host disease (cGvHD) compared with allogeneic hematopoietic stem cell transplant (alloHSCT) in the phase 3